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Abstract The bone disease that occurs as a result of chronic
kidney disease (CKD) is not only debilitating but also linked
to poor growth and cardiovascular disease. It is suspected that
abnormal bone turnover is the main culprit for these poor
outcomes.Plasmaparathyroidhormone (PTH)levelsare used
as a surrogate marker of bone turnover, and there is a small
number of studies in children that have attempted to identify
the range of PTH levels that correlates with normal bone
histology. It is clear that high PTH levels are associated with
high bone turnover, although the range is wide. However, the
ability of PTH levels to distinguish between low and normal
bone turnover is less clear. This is an important issue, because
current guidelinesfor calcium andphosphate managementare
based upon there being an “optimum” range for PTH. This
editorial takes a critical look at the evidence upon which these
recommendations are based.
Keywords Parathyroidhormone(PTH).Boneturnover.
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Introduction
Abnormal mineral metabolism and altered bone structure and
composition occur early in the course of chronic kidney
disease (CKD). If untreated, bony deformities can result,
affecting both mobility and growth. Although such severe
effects are now rarely seen, bone-related problems that
adversely affect quality of life, including bone and joint pain
and fractures, are the most common complaints in young adult
survivors of paediatric renal failure programmes [1]. Further-
more, it is not only morbidity but also mortality that is affected
by abnormal mineral metabolism: the association with extra
skeletal and, in particular, vascular calcification, is strongly
suggestive of a causative link, although the pathological
mechanisms are yet to be unravelled. In order to reflect the
complex issues surrounding these areas, it has been suggested
that CKD-mineral and bone disorder (CKD-MBD) should be
used as an encompassing definition and “renal osteodystrophy”
be reserved for description of bone morphology [2].
The importance of the optimum range for parathyroid
hormone
Current management of CKD-MBD hinges on the concept of
an optimum range for plasma parathyroid hormone (PTH)
levels, which is a range that maintains normal bone turnover
without increasing the risk for ectopic calcification. This range
may change with time, as abnormalities in PTH secretion and
bone turnover begin to occur early in the course of CKD and
can lead to increasing skeletal resistance to PTH as CKD
progresses. Therefore, increasingly higher PTH levels are
necessary to maintain normal bone turnover, and a higher
plasma calcium level is needed to suppress PTH secretion,
unless normal mineral metabolism is maintained. Hyperpara-
thyroidism evolves, because phosphate retention, decreased
dietary intake of calcium and vitamin D, and decreased
synthesis of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] in
the kidney act to increase PTH secretion via the calcium
sensingreceptors(CaSRs)andthevitaminDreceptors(VDRs)
in the parathyroid gland. Persistent parathyroid stimulation
results in parathyroid hyperplasia, reduced VDR and CaSR
expression, less suppression of PTH by calcium and 1,25(OH)
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needforparathyroidectomy.Whatisnotknowniswhetherthis
process can be prevented if mineral metabolism and PTH
levels are maintained within the normal range throughout the
course of CKD, so that the parathyroid gland is never allowed
to escape normal control mechanisms [3].
Bone tissue is formed by osteoblasts, maintained by
osteocytes and resorbed by osteoclasts. Activity is increased
by PTH. The spectrum of bone abnormality ranges from low
bone turnover [adynamic bone disease (ABD)], when there is
normal or reduced osteoid and low or diminished numbers of
osteoclasts and osteoblasts, to high bone turnover, when there
are increased osteoclasts and bone resorption, increased
osteoblasts and bone formation, and increased osteoid and
non-lamellar bone. A mixed picture can also occur. The
optimum range for PTH is one that maintains normal bone
turnover.PTHlevelscanbemanipulatedintothisrangebythe
control of plasma calcium and phosphate by diet, phosphate
binders, dialysis and prescription of vitamin D. Maintaining
normal bone turnover is important for two reasons: firstly, to
prevent bone deformity, pain and fractures and to optimise
growth; and secondly, to prevent soft tissue calcification. The
risks of extra skeletal calcification are thought to be increased
with both low and high bone turnover, because both types
result in high plasma calcium and phosphate levels: low bone
turnover because of the inability of bone to buffer changes in
plasma calcium and phosphate, and high turnover because
high PTH levels mobilise calcium and phosphate from bone,
increase tubular reabsorption of calcium, and promote gut
absorption of calcium and phosphate by hydroxylation of 25,
OHD3. Furthermore, PTH itself is thought to be an
independent risk factor for myocardial fibrosis, arteriolar
thickening, and hypertension [4].
Current guidelines for PTH management
There are detailed guidelines from the USA [Kidney
Disease Outcomes Quality Initiative (KDOQI)] [5] and
Europe [6] on PTH management, and all aspects of calcium,
phosphate and vitamin D control, in order to achieve these
aims. European recommendations for CKD are that the
plasma PTH should be kept in the normal range until stage 5,
when 2-to3-times the upper limit ofnormalisrecommended.
KDOQI sets higher levels of up to twice the upper limit of
normal in CKD stage 4 and 3- to 5-times on dialysis. Clearly,
if we are to minimise the morbidity and mortality from CKD-
MBD itisvital thatwe“get itright”. But whatifwehave “got
it wrong“? Many of our data have been extrapolated from
studies of adults, but active bone growth in children and their
requirements for more calcium and phosphate may present a
different homoeostatic mechanism. Furthermore, is there
sufficient evidence to allow us to prescribe one set of
guidelines for all? For example, should the child presenting
antenatally whose condition is managed with normal range
PTH levels suddenly change treatment to allow PTH levels of
2-to3-timesnormalatstage5CKDaspercurrentguidelines?
Surely such a child is different from one who first presents in
stage 5 CKD who has had many years of uncontrolled
hyperparathyroidism? What about the effect of variable
plasma phosphate control, which will independently affect
PTH levels? Finally, there has to be a word of caution about
the value of PTH as a marker of bone turnover; its short half-
lifemeansthatfluctuationsareverylikely,andthe presenceof
PTH fragments, which are detected by the majority of current
assays, may increase with the severity of both CKD and
hyperparathyroidism [7].
What is the evidence for the optimum range for plasma
PTH levels?
PTH levels, bone turnover and bone biopsies
Clearly,theonlywaywecanknowtherateofboneturnoveris
by bone biopsy, but this is an invasive and expensive
procedure, currently undertaken in very few paediatric
centres. PTH is, therefore, currently used as the best available
surrogate marker of bone turnover. Recommendations for
optimum PTH levels are based on the pioneering work of
Salusky, who has been the leader in the field of paediatric
bone biopsy and who has been able to correlate plasma PTH
levels with bone turnover [8, 9, 10]( T a b l e1, Fig. 1).
The first description of bone histology in children with
CKD was from Australia in 1982. Bone abnormalities
included high turnover, osteomalacia and mixed lesions and
were present in all 23 children with a glomerular filtration
rate (GFR) <20 ml/min per 1.73 m
2 body surface area. PTH
levels were high, but the assay available at that time picked
up carboxy terminal fragments as well as the intact
hormone [11]. A paper from Toronto in 1988 showed that
treatment with 1 alpha-hydroxycholecalciferol resulted in
significant improvement in PTH levels and bone histology
in 12 peritoneal dialysis (PD) patients [12]. There are five
paediatric studies since 1990, and unpublished data from
our centre, that have used newer “intact” PTH assays to
look at their correlation with bone histology (Table 1). The
first three studies [8, 9, 10] are all from Salusky’s group,
and are of patients dialysed in their unit between 1983 and
1992. There are two more recent studies from Poland [13]
and Turkey [14]. The patients from our unit had bone
biopsies taken prior to starting dialysis, at the time of
insertion of access or at transplantation.
High-turnoverbonewas characterisedby PTH levels above
normal in all studies, although the variation was wide, ranging
from just above the upper limit of normal (76±14 pg/ml),
180 Pediatr Nephrol (2008) 23:179–184when changes were mild [8], to 16-times normal (1,122±
603 pg/ml) with osteitis fibrosa [15].
Patients with ABD clearly had lower PTH levels than
those with osteitis fibrosa (although not lower than those
with mild hyperparathyroidism) [8]. However, the ability of
PTH levels to distinguish between ABD and normal
histology is less clear. Figure 1 shows the PTH levels in
the three studies that have identified patients with normal
bone and ABD. Even within the same centre, there was no
consistency, with PTH levels being lower with normal bone
than with ABD in patients on haemodialysis (HD) [8], but
the reverse in PD patients [9]. Levels were particularly high
in the second study, with a wide scatter, but analysis of
results in these patients suggested that PTH <150 pg/ml and
calcium >10 mg/dl (>2.50 mmol/l) was indicative of low
turnover, and PTH >200 pg/ml with calcium <10 mg/dl
(2.50 mmol/l) indicated high turnover [9]. In the Polish
group a PTH level of <50 pg/ml was suggestive of ABD,
but the difference from normal bone was not significant
[13]. Other evidence for PTH levels associated with ABD
comes from a study of the role of intermittent oral
administration compared with intraperitoneal administration
of calcitriol (dose 1.26 (0.61–2.88) μg×3 per week for a
year) in 14 patients with high-turnover disease. There were
no patients with normal histology results. Six patients
developed ABD, with a mean PTH of approximately
200 pg/ml, whereas the mean for high-turnover disease
was around 400 pg/ml. However, again, the standard errors
were wide [10].
What are the potential problems with these studies? Patient
numbersaresmallinsome;thereareveryfewyoungchildren,
and, indeed, some patients might have ceased growing; some
children in the earlier studies had received aluminium, and
two had undergone parathyroidectomies (both recognised
causes of ABD); some had transplants that had failed;
phosphate control and vitamin D doses were variable, and
the majorityreceiveddialysate calcium of1.75mmol/l,which
is higher than is most commonly used now.
PTH levels and growth
Intuitively, it might be expected that poor growth would
occur with ABD, and, conversely, that, if a child is growing
well, ABD is unlikely. The only published paper to look at
bone histology and growth is by Salusky’s group in 1998
[15]. Their purpose was also to study the effect of different
ways of administering vitamin D. Sixteen patients were
treated for a year with intermittent doses of calcitriol in
comparison to daily treatment during the preceding year.
The rate of growth was unchanged in the patients taking
calcitriol daily, but, in the patients taking intermittent doses
of calcitriol, PTH correlated with the change in height
standard deviation score (HtSDS). Growth was particularly
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Pediatr Nephrol (2008) 23:179–184 181affected in the four patients who developed ABD, possibly
because of the inhibiting effects of large, intermittent, doses
of calcitriol on chondrocyte activity within the growth plate
cartilage. In our 11 patients (Table 1) the rate of growth did
not vary with the type of bone histology. Change in HtSDS
over the previous 1.0 (0.5–1.6) years was +0.06 (−0.11 to
+0.15) in patients with ABD, −0.29 (−0.07 to −0.50) in
those with mixed lesions, and 0.02 (−0.34 to+0.34) in
patients with high-turnover disease. However, numbers are
small, and only much larger studies would be able to clarify
the relationship between growth and bone histology.
Overall, reports of growth in children on dialysis are
variable, with the majority showing a decline in HtSDS. It
is difficult to dissect out the effects of renal bone disease
from malnutrition, anaemia, inadequate dialysis and other
causes of poor growth. On the other hand, we have found,
in a review of the growth of 35 prepubertal children on
dialysis for more than 1 year in our unit, that, even with
PTH levels only slightly above normal, it is possible to
prevent decline in HtSDS, and significant catch-up growth
can occur in children less than 2 years [16, 17].
PTH levels and vascular disease
Adynamic bone disease due to aging, parathyroidectomy,
aluminium and high doses of calcium-containing phosphate
binders is associated with vascular calcification in adults
[18]. Is there any evidence to associate PTH levels and
vascular disease and calcification in children? This is a
difficult question to answer, because of the inextricable
relationships between phosphate, which is possibly the
most potent vascular toxin, vitamin D, and PTH. Soft tissue
calcification in paediatric patients is not a new phenome-
non. The presence of coronary artery abnormalities at post-
mortem in children who had been on HD was reported as
long ago as 1976 [19], and autopsies of 120 children with
uraemia, on dialysis, or following renal transplantation
from 1960 to 1983 revealed soft tissue calcification in 60%
[20]. More recently, histological evidence of intimal
thickening and atherosclerotic plaques was found in five
of 12 children with a mean (range) age of 14.6 (11–17)
years on HD who were undergoing transplantation and was
associated with calcification in the iliac artery of two [21].
Most studies of the effect of childhood end-stage renal
failure (ESRF) on vascular outcomes are of young adults.
As well as survival data, surrogate markers of structural and
functional disease and calcification, such as carotid intima
media thickness (CIMT) and distensibility, and pulse wave
velocity (PWV), electron beam computed tomography
(EBCT) and multi-slice CT scanning have been used to
assess the development of vascular abnormality. Inevitably,
because a significant number of patients in these follow-up
cohorts have died from cardiovascular disease, the true
incidence and severity of vascular abnormalities is likely to
be greater than reports using surrogate markers would
suggest. Duration of ESRF management and, in particular,
dialysis, has been linked to worse outcomes in all studies.
Not all studies have addressed the effect of abnormalities
of mineral metabolism on vascular anomalies; arterial
stiffness was shown to be increased in the Dutch long-term
follow-up study, but data on mineral metabolism were not
available [22]. In a study from Germany, coronary artery
calcification (CAC) was reported in 38% of 16 patients
aged 14–39 years, but correlations with PTH were not made
[23]. Three studies have concentrated on this aspect in
young adults. In a second German study, CAC was found in
92% of 39 patients aged 19–39 years on dialysis or after
transplantation, and CIMT was increased. Calcification
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182 Pediatr Nephrol (2008) 23:179–184scores and CIMT correlated with the calcium × phosphate
product and with PTH, particularly if the level of C-reactive
protein (CRP) was raised [24]. A further study from
Salusky’s group identified CAC in 88% of 16 patients aged
over 20 years on dialysis, but in none of 23 patients aged less
than this. The plasma calcium, calcium x phosphate product
and intake of calcium, but not PTH levels, were greater in
those with calcification [25]. The most recent paper included
40 patients aged 23.6±5.5 years, of whom nine were on
dialysis and 31 had received transplants. CIMT was not
increased, but left ventricular hypertrophy was present in
62.5%, and four (10%) had CAC. Again, calcium intake
from phosphate binders and vitamin D correlated with these
abnormalities, and PTH was an independent predictor of left
ventricle (LV) mass index [26].
There are five studies that address the problem princi-
pally in children, although in four of these studies patients
in their twenties are included, i.e. patients who no longer
have the dimension of growth affecting mineral balance.
Increased plasma phosphate, calcium phosphate product,
phosphate binder and calcitriol doses, and PTH predicted
abnormal vascular structure and function, and PTH also
correlated with left ventricle mass (LVM) index and poor
diastolic function, in 16 patients on dialysis [27]. CIMT
was increased in 37 patients on dialysis and in 34 after
transplantation, particularly in the dialysis patients, and
CIMT correlated with calcium × phosphate product,
calcium-based phosphate binder and vitamin D intake, but
not with PTH [28]. Spiral CTscanning in 53 patients (39 on
dialysis, 14 after transplantation) detected CAC in 15%.
Mineral metabolism was a significant association, including
higher time integrated phosphate, calcium × phosphate
product and PTH, and calcium-containing phosphate bind-
ers and vitamin D intake [29]. A recent paper from the USA
of 11 patients (four on HD, seven after transplantation)
reported that seven had CAC. This included all the patients
on dialysis. The only significant influencing factor was the
dose of calcitriol. PTH levels were very high in all patients
[30]. We have studied CIMT, PWVand CAC in 85 children
of a younger age range (5 years to 18 years) who had
undergone dialysis for at least 6 months. CIMT and
calcification correlated with PTH levels. There was no
difference from controls in CIMT and PWV in patients with
PTH levels < 2 × the upper limit of normal (44 children),
but those with PTH levels > 2 × the upper limit of normal
(ULN) (41 children) had thicker CIMT, stiffer vessels and
increased calcification. The dose of vitamin D strongly
influenced all vascular measures [31]. Further investigation
of 61 children on dialysis identified a bimodal effect of
plasma levels of 1,25 (OH)2D3, such that levels both above
and below the normal range were associated with increased
CIMT and vascular calcification [32]. In summary, PTH
was correlated with surrogate markers of vascular calcifi-
cation in three out of the five paediatric studies [27, 29, 31]
and two out of the three studies of young adults that have
looked at this relationship [24, 26].
Conclusions
The evidence for optimum levels for PTH management in
children with CKD is weak. This means that our current
recommendations for manipulation of plasma calcium and
phosphate, which are based upon controlling PTH within a
specified range, may be flawed as a result, particularly in the
light ofemerging datasuggestinga protective effectof atleast
small doses of vitamin D in cardiovascular health [33]. So
whatshouldourapproachbe?Wewanttoprovideourpatients
with the best outcome for bone health, growth and cardiovas-
cular disease. We do know that hyperphosphataemia and a
high calcium × phosphate product are toxic to the vasculature
andshouldbeprevented.Weknowthatbothtoomuchandtoo
little intake of calcium is bad. We know that high PTH levels
and plasma levels of vitamin D that are either too low or too
high are associated with increased cardiovascular morbidity.
Clearly,therefore,weneedtokeepplasmaphosphate,calcium
and vitamin D levels in the normal range. Is there enough
evidence in children to manipulate PTH levels to such
abnormally high values as currently recommended by
KDOQI and the European guidelines? Can intervention early
in the course of CKD prevent the escape of the parathyroid
glandfromnormalcontrolmechanisms?Currently,untilmore
research becomes available, recommendations can only be
opinion based, and, therefore, consensus may be difficult.
However, as growth rate can be maintained, and surrogate
markers of cardiovascular disease are at their best in dialysed
children with PTH levels of < 2 × ULN, I would like to
recommendthatthisshouldbetheupperlimitoftherangethat
we should aim for in children with CKD stage 5.
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